Clinical trial to evaluate role of Tripada Guggul Vati as adjuvant treatment in Madhumeha Type2 DM

Randomised Controlled Clinical trial To Evaluate The Efficacy Of Adjuvant Effect Of Tripada Guggul(Susrutokta)Vati In Madhumeha Vis-A-vis Diabetes Mellitus Type 2

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/07/020141

Enrollment

200

Registered

2019-07-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Tripada Guggul Vati (500mg Rasayan kal and Pragbhat kal)morning and evening empty stomach as an adjuvant treatment with OHA (metformin as prescribed): Subjects in trial group who will b

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with Signs & Symptoms of Madhumeha (hastapadtaladaha, pipasa, kshudhavridhhi, prabhutmootrata, avilmootrata, naktamootrata, Daurbalya, swedativrudhhi) 2. Age : 25 years to 60 years of either gender. 3. K/C/O Type 2 Diabetes Mellitus from 1- 5 years 4. BSL - F >126 mg/dl & BSL-PP > 200 mg/dl up to 300mg/dl 5. HbA1c â??

Exclusion criteria

Exclusion criteria: 1.Known cases of TYPE-1 Diabetes Mellitus 2. Patients with any major systemic complications of DM. 3. Patients having any other major illness. 4. Known case of gestational diabetes.

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of an adjuvant effect of Tripada Guggul (Susrutokta) VatiTimepoint: 90 days	—

Secondary

Measure	Time frame
1.To evaluate the efficacy of drug in achieving glycaemic control on the basis of HbA1c , BSL-fasting , BSL-post prandial state, urine sugar fasting and post prandial. 2.To evaluate the efficacy of drug on subjective parameters like kshudhavridhhi, pipasa, prabhutamutrata, Naktamutrata, Avil mutrata, hastapadtal daha, daurbalya, swedativrudhhi. 3.To observe the effect of drug on body weight. 4.To observe the effect of drug on B.M.I. Timepoint: HbA1cat day 0 and day 90, BSL-fasting/BSL-PP, urine sugar fasting and PP done monthly for 90 days. 2.To evaluate the efficacy of drug on subjective parameters like kshudhavridhhi, pipasa, prabhutamutrata, Naktamutrata, Avil mutrata, hastapadtal daha, daurbalya, swedativrudhhi.	—

Measure

Time frame

1.To evaluate the efficacy of drug in achieving glycaemic control on the basis of HbA1c , BSL-fasting , BSL-post prandial state, urine sugar fasting and post prandial. 2.To evaluate the efficacy of drug on subjective parameters like kshudhavridhhi, pipasa, prabhutamutrata, Naktamutrata, Avil mutrata, hastapadtal daha, daurbalya, swedativrudhhi. 3.To observe the effect of drug on body weight. 4.To observe the effect of drug on B.M.I. Timepoint: HbA1cat day 0 and day 90, BSL-fasting/BSL-PP, urine sugar fasting and PP done monthly for 90 days. 2.To evaluate the efficacy of drug on subjective parameters like kshudhavridhhi, pipasa, prabhutamutrata, Naktamutrata, Avil mutrata, hastapadtal daha, daurbalya, swedativrudhhi.

—

Countries

India

Contacts

Public ContactDr Shachi Desai

MAMs Sumatibhai Shah Ayurved Mahavidyalay

jntayu@gmail.com9822829493

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026